
Respiratory viral infections occur more frequently during the winter months1 and are a risk factor for respiratory exacerbations:2,3

Upper respiratory infections represent a significant disease burden with 17.2 billion incident cases in 2019 globally.4

Respiratory exacerbations, when associated with viral respiratory infections, are typically more severe, last longer and increase the risk of hospitalisation.2,3
There are several factors to consider when choosing an aerosol drug delivery device:
Fugitive emissions
Fugitive emissions are a concern when patients are harbouring respiratory viral infections.2Support during escalation of care
Patients admitted to hospital during exacerbations may receive respiratory support (e.g., high-flow therapy [HF]) or ventilatory support (e.g., non-invasive ventilation [NIV], invasive mechanical ventilation [IMV]).2,3
Patient distress during respiratory exacerbations
On presentation, children may be crying or in distress, which may negatively impact the dose delivered during inhaled therapy. 5,6
Aerogen: supporting you through winter
In a study of patients in an emergency department requiring treatment with an aerosolised bronchodilator:
0
of patients achieved symptom control with one 2.5 mg salbutamol dose 7
0
median reduction in ED length of stay per patient with Aerogen Ultra versus jet nebuliser 7
0
reduction in admission rates with Aerogen Ultra versus jet nebuliser 7
0
higher discharge rate with Aerogen Ultra versus jet nebuliser 7
Aerogen helps mitigate fugitive emissions8,9
Significantly lower fugitive aerosol concentrations were reported with Aerogen and mask or mouthpiece versus jet nebuliser during self-ventilation (P<0.05)†8
Aerogen can be used throughout the hospital10
If escalation of care is required, the Aerogen Solo system can facilitate aerosol drug delivery at every stage of a patient's respiratory journey (SV, HF, NIV, IMV),10 supporting continuity of care.
Aerogen supports a calm environment
Quick and easy to set up10
Virtually silent during drug delivery10,11
Compatible with all standard aerosol/valved face masks, to meet varied patient needs10
Aerogen Solo
Aerogen Solo can support aerosol drug delivery at every stage of a patient’s respiratory journey: during IMV, NIV, HF and SV.1
- Quick and easy to set up10
- Virtually silent10,11
- Single patient use10
- 28 days intermittent or 7 days continuous use10
- No added flow10
- Refill medication cup without opening the circuit10
- 6 mL cup10
- Can be placed at the wye or at the humidifier10


Enquiries
The Aerogen team and our representatives are available globally to answer your questions, provide an online demonstration and place orders
†Defined as fugitive aerosol concentrations with jet nebuliser vs Aerogen with a mask at particle sizes of 1.0–5 μm and with a mouthpiece at particle sizes of 0.5–3 μm (all P<0.05) when self-ventilating. Study performed in healthy subjects.
- Moriyama M, Hugentobler WJ, Iwasaki A. Annu Rev Virol. 2020;7(1):83-101.
- 2022 GINA Report, Global Strategy for Asthma Management and Prevention. Available at: www.ginasthma.org/gina-reports/ Accessed: September 2023.
- Global Initiative for Chronic Obstructive Lung Disease: Global strategy for prevention, diagnosis and management of COPD, 2023. Available at: www.goldcopd.org/2023-gold-report-2/. Accessed: September 2023.
- Jin X, Ren J, Li R, et al. EClinicalMedicine. 2021;37:100986.
- Ari A. Ann Transl Med. 2021;9(7):593.
- Corcoran TE. Ann Transl Med. 2021;9(7):595.
- Dunne RB, Shortt S. Am J Emerg Med. 2018;36(4):641-646.
- Harnois LJ, Alolaiwat AA, Jing G, Fink JB, Dhand R, Li J. Respir Care. 2022;67(4):394-403.
- McGrath JA, O’Sullivan A, Bennett G, et al. Pharmaceutics. 2019;11(2):75.
- 30-354 Rev U Aerogen Solo System Instruction Manual.
- Royal National Institute for Deaf People (RNID). How loud is too loud? Available at: https://rnid.org.uk/information-and-support/ear-health/protect-your-hearing/how-loud-is-too-loud/ Accessed: November 2023
GL-2220-1-EN